Vyome Holdings (HIND) Total Non-Current Liabilities (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Total Non-Current Liabilities of $1.8 million for Q1 2026, down 55.98% year-over-year from $4.1 million in Q1 2025, and down 24.5% quarter-over-quarter from $2.4 million in Q4 2025.
Vyome Holdings (HIND) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Vyome Holdings' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 55.98% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (down 55.98% YoY), while the FY2025 annual figure was $2.4 million, up 7247.23% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $1.8 million, down from $2.4 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $9.6 million in Q2 2022, with the low at $8151.0 in Q3 2025.
- The 5-year median for Total Non-Current Liabilities is $4.0 million (2023), against an average of $4.2 million.
- Peak annual rise in Total Non-Current Liabilities reached 7247.23% in 2025, while the deepest fall reached 99.8% in 2025.
- Vyome Holdings' Total Non-Current Liabilities stood at $9.6 million in 2022, then slumped by 58.98% to $3.9 million in 2023, then plunged by 99.16% to $32830.0 in 2024, then surged by 7247.23% to $2.4 million in 2025, then fell by 24.5% to $1.8 million in 2026.
- Business Quant data shows HIND's Total Non-Current Liabilities at $1.8 million in Q1 2026, $2.4 million in Q4 2025, and $8151.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Dec 31, 2025 | 2.41 Mn |
| Sep 30, 2025 | 8,151.00 |
| Mar 31, 2025 | 4.14 Mn |
| Dec 31, 2024 | 32,830.00 |
| Sep 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 3.30 Mn |
| Mar 31, 2024 | 3.65 Mn |
| Dec 31, 2023 | 3.93 Mn |
| Sep 30, 2023 | 4.64 Mn |
| Jun 30, 2023 | 4.60 Mn |
| Mar 31, 2023 | 7.60 Mn |
| Jun 30, 2022 | 9.58 Mn |
| Mar 31, 2022 | 8.62 Mn |
| Dec 31, 2021 | 7.90 Mn |
| Sep 30, 2021 | 10.18 Mn |
| Jun 30, 2021 | 61.84 Mn |
| Mar 31, 2021 | 7.21 Mn |
| Dec 31, 2020 | 21.55 Mn |